Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMRIX vs AMOXAPINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Selective inhibitor of serotonin reuptake and, to a lesser extent, norepinephrine reuptake. Also exhibits weak dopamine D2 receptor antagonism and alpha1-adrenergic blockade.
Treatment of spasticity due to multiple sclerosis, spinal cord injury, or other spinal cord disorders
Major depressive disorder,Anxiety,Panic disorder,Off-label: neuropathic pain, insomnia
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
200-300 mg/day orally in divided doses, initially 50 mg three times daily; maximum 400 mg/day
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
Parent drug: 8-12 hours; active metabolite (8-hydroxyamoxapine): approximately 30 hours; steady-state achieved in 3-5 days
Hepatic via deamination; primarily metabolized by monoamine oxidase B (MAO-B) to inactive metabolites.
Primarily hepatic via CYP2D6 and CYP3A4; major metabolite is 8-hydroxyamoxapine, which is pharmacologically active.
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
Primarily renal (approximately 60-70% as metabolites, <5% unchanged); minimal fecal elimination (<10%)
40–45% bound to serum proteins, primarily albumin
Approximately 80-90%, primarily to albumin and alpha-1-acid glycoprotein
5–8 L/kg; suggests extensive tissue distribution, including skeletal muscle
0.8-1.2 L/kg, indicating extensive tissue distribution
Oral: 85–95% (extended-release formulation)
Oral: approximately 60-70% due to first-pass metabolism
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min).
GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use or reduce dose by 75%
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B: initiate at 15 mg once daily; do not increase dose. Use with caution.
Child-Pugh Class A: start at 25 mg twice daily; Class B: 25 mg once daily; Class C: avoid use
Safety and efficacy not established in pediatric patients under 12 years. For ages 12 and older, same as adult dosing.
Not recommended for use in children under 16 years
Initiate at 15 mg once daily. Due to higher incidence of anticholinergic effects and falls, monitor closely; consider lower doses in frail elderly.
Initial dose 25 mg twice daily, increase slowly; maximum 300 mg/day
None
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Abrupt discontinuation may precipitate withdrawal syndrome including hallucinations, seizures, autonomic instability.,May cause sedation, dizziness, and muscle weakness; caution with activities requiring alertness.,Use with caution in patients with impaired renal function due to reduced clearance.,May exacerbate seizures in patients with epilepsy.,Avoid concomitant use with other CNS depressants.
Suicidality risk in young adults,Serotonin syndrome when combined with other serotonergic drugs,Extrapyramidal symptoms due to weak D2 blockade,Seizure risk,Cardiotoxicity (prolonged QT interval) at high doses,Agranulocytosis (rare)
Hypersensitivity to amrix or baclofen.,Abrupt withdrawal is contraindicated; must be tapered.,Concomitant use with MAO inhibitors is contraindicated due to risk of hypertensive crisis.
Hypersensitivity to amoxapine or any dibenzoxazepine,Concomitant use with MAOIs (including linezolid and methylene blue),Recent myocardial infarction,Uncontrolled narrow-angle glaucoma,Urinary retention,QT prolongation or concurrent use of drugs that prolong QT
Avoid grapefruit and grapefruit juice during treatment as they may increase cyclobenzaprine levels. Taking AMRIX with or without food does not significantly affect absorption. Alcohol should be strictly avoided as it potentiates CNS depression.
Avoid alcohol and beverages with high tyramine content (e.g., aged cheese, cured meats, fermented foods) only if patient is also on MAOIs; not a specific requirement for amoxapine alone. Grapefruit juice may inhibit metabolism; advise caution or avoid large amounts. For patients with hypertension or seizure disorders, avoid excessive caffeine.
Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacking. Use only if clearly needed. First trimester: no specific teratogenic effects documented; second and third trimesters: avoid near term due to potential neonatal effects (e.g., sedation, withdrawal).
First trimester: Limited data; risk of neural tube defects? Second trimester: No specific associations. Third trimester: Risk of neonatal withdrawal (irritability, feeding difficulties). Overall: FDA Category C; avoid in first trimester if possible.
Cyclobenzaprine is excreted into human milk in small amounts. M/P ratio: not established. Use with caution in nursing mothers; monitor infant for sedation, poor feeding, or hypotonia.
Excreted in breast milk; M/P ratio not established. Use caution due to potential for infant sedation and anticholinergic effects; monitor for drowsiness and poor feeding.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy; however, due to potential for increased clearance, lowest effective dose should be used. Avoid use during labor and delivery due to potential neonatal depression.
No established dose adjustments; increased clearance in pregnancy may require dose increase to maintain efficacy; monitor therapeutic response and serum levels if available.
AMRIX (cyclobenzaprine extended-release) should not be used longer than 2-3 weeks due to lack of evidence for efficacy in muscle spasm beyond that period. It has significant anticholinergic effects; avoid in patients with glaucoma, urinary retention, or those taking MAOIs. Do not crush or chew capsules; administer once daily at same time. Onset of action is delayed compared to immediate-release cyclobenzaprine.
Amoxapine is a dibenzoxazepine antidepressant with both tricyclic-like reuptake inhibition and dopamine receptor blocking properties. Monitor for extrapyramidal symptoms (EPS) and tardive dyskinesia, especially in elderly. Due to dopamine blockade, it may cause hyperprolactinemia. For patients with seizures, use cautiously; dose-dependent seizure risk is higher than with other TCAs. Onset of antidepressant effect may be 2-4 weeks. Use lower initial doses in elderly and hepatic impairment. Avoid in recent myocardial infarction.
Take AMRIX exactly once daily at the same time each day; do not crush, chew, or open the capsule.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase the risk of severe drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how AMRIX affects you; it may cause drowsiness, dizziness, or blurred vision.,Contact your healthcare provider if you experience symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness, nausea, diarrhea).,Do not use AMRIX for longer than 2-3 weeks unless specifically directed by your doctor; prolonged use is not recommended.,Inform your doctor if you have a history of urinary retention, glaucoma, thyroid disorders, heart problems, or liver disease.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.
Take exactly as prescribed; do not increase or stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how the medication affects you.,Avoid alcohol and other CNS depressants.,Report any muscle stiffness, tremor, restlessness, or unusual movements of the face or tongue.,Notify your doctor if you experience rapid or irregular heartbeat, difficulty urinating, or blurred vision.,May cause dry mouth; use sugarless candy or gum and maintain good oral hygiene.,Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Do not take any other medications, including over-the-counter products, without approval from your healthcare provider.
No interactions on record
"Combined use of Oxprenolol, a non-selective beta-blocker with intrinsic sympathomimetic activity, and Amoxapine, a tricyclic antidepressant, may lead to additive cardiovascular adverse effects. Amoxapine can inhibit the metabolism of beta-blockers via competition for CYP450 enzymes, increasing oxprenolol plasma concentrations. This interaction heightens the risk of bradycardia, hypotension, and may precipitate heart block or arrhythmias, particularly in patients with pre-existing cardiac disease."
"The combination of amoxapine, a tricyclic antidepressant with strong anticholinergic properties, and clidinium, a quaternary ammonium anticholinergic used for gastrointestinal spasms, results in additive anticholinergic effects. This can lead to excessive peripheral and central anticholinergic adverse effects such as dry mouth, blurred vision, constipation, urinary retention, tachycardia, cognitive impairment, and exacerbation of glaucoma or paralytic ileus. In severe cases, anticholinergic toxicity may manifest as hyperthermia, delirium, or seizures, particularly in elderly patients or those with pre-existing conditions."
"Telavancin, a lipoglycopeptide antibiotic, prolongs the QT interval by inhibiting the delayed rectifier potassium current (IKr) in cardiac myocytes. Amoxapine, a tricyclic antidepressant, also blocks cardiac sodium and potassium channels, leading to dose-dependent QTc prolongation. Concomitant use increases the risk of torsade de pointes, ventricular arrhythmias, and sudden cardiac death, particularly in patients with electrolyte imbalances, bradycardia, or preexisting QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMRIX vs AMOXAPINE, answered by our medical review team.
AMRIX is a Muscle Relaxant that works by Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.. AMOXAPINE is a Tricyclic Antidepressant that works by Selective inhibitor of serotonin reuptake and, to a lesser extent, norepinephrine reuptake. Also exhibits weak dopamine D2 receptor antagonism and alpha1-adrenergic blockade.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMRIX and AMOXAPINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMRIX is: 15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.. The standard adult dose of AMOXAPINE is: 200-300 mg/day orally in divided doses, initially 50 mg three times daily; maximum 400 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMRIX and AMOXAPINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMRIX is classified as Category C. Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacki. AMOXAPINE is classified as Category C. First trimester: Limited data; risk of neural tube defects? Second trimester: No specific associations. Third trimester: Risk of neonatal withdrawal (irritability, feeding difficul. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.